

**OBESITY TREATMENT AGENTS
PRIOR AUTHORIZATION FORM**
(form effective 1/1/2026)



Keystone First

PERFORMRxSM
Next Generation Pharmacy Benefits

Fax to PerformRxSM at **1-866-497-1387**, or to speak to a representative, call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages:	Name of office contact:
Contact's phone number:		LTC facility contact/phone:	
BENEFICIARY INFORMATION			
Beneficiary name:		Beneficiary ID #:	DOB:
PRESCRIBER INFORMATION			
Prescriber name:			
Specialty:	State license #:	NPI:	
Street address:		City/state/zip:	
Phone:	Fax:		
CLINICAL INFORMATION			
DRUG REQUESTED***:			
***NOTE: Requests for drugs containing a GLP-1 receptor agonist should use the GLP-1 Receptor Agonists fax form. GLP-1 receptor agonists are not covered for the treatment of overweight or obesity.			
Strength:	Dosage form:	Quantity:	Refills: _____
Directions:			
Diagnosis (<i>submit documentation</i>):			Dx code (<i>required</i>):
Does the beneficiary have any contraindications to the requested drug?			<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
ATTESTATION from the prescriber: Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?			<input type="checkbox"/> Yes <input type="checkbox"/> No

**Complete all sections that apply to the beneficiary and this request.
Check all that apply and submit documentation for each item.**

INITIAL REQUESTS																		
<p>1. The beneficiary is 18 years of age or older and: Pre-treatment weight: _____ Pre-treatment BMI: _____</p> <p><input type="checkbox"/> Has a BMI greater than or equal to 30 kg/m²</p> <p><input type="checkbox"/> Has a BMI greater than or equal to 27 kg/m² and less than 30 kg/m² AND at least one of the following weight-related comorbidities:</p> <table border="0"> <tr> <td><input type="checkbox"/> cardiovascular disease</td> <td><input type="checkbox"/> metabolic syndrome</td> </tr> <tr> <td><input type="checkbox"/> dyslipidemia</td> <td><input type="checkbox"/> obstructive sleep apnea</td> </tr> <tr> <td><input type="checkbox"/> hypertension</td> <td><input type="checkbox"/> prediabetes</td> </tr> <tr> <td><input type="checkbox"/> metabolic syndrome</td> <td><input type="checkbox"/> type 2 diabetes</td> </tr> <tr> <td><input type="checkbox"/> Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. AND has at least one of the following weight-related comorbidities:</td> <td><input type="checkbox"/> other (list): _____</td> </tr> <tr> <td><input type="checkbox"/> cardiovascular disease</td> <td><input type="checkbox"/> obstructive sleep apnea</td> </tr> <tr> <td><input type="checkbox"/> dyslipidemia</td> <td><input type="checkbox"/> prediabetes</td> </tr> <tr> <td><input type="checkbox"/> hypertension</td> <td><input type="checkbox"/> type 2 diabetes</td> </tr> <tr> <td></td> <td><input type="checkbox"/> other (list): _____</td> </tr> </table>	<input type="checkbox"/> cardiovascular disease	<input type="checkbox"/> metabolic syndrome	<input type="checkbox"/> dyslipidemia	<input type="checkbox"/> obstructive sleep apnea	<input type="checkbox"/> hypertension	<input type="checkbox"/> prediabetes	<input type="checkbox"/> metabolic syndrome	<input type="checkbox"/> type 2 diabetes	<input type="checkbox"/> Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. AND has at least one of the following weight-related comorbidities:	<input type="checkbox"/> other (list): _____	<input type="checkbox"/> cardiovascular disease	<input type="checkbox"/> obstructive sleep apnea	<input type="checkbox"/> dyslipidemia	<input type="checkbox"/> prediabetes	<input type="checkbox"/> hypertension	<input type="checkbox"/> type 2 diabetes		<input type="checkbox"/> other (list): _____
<input type="checkbox"/> cardiovascular disease	<input type="checkbox"/> metabolic syndrome																	
<input type="checkbox"/> dyslipidemia	<input type="checkbox"/> obstructive sleep apnea																	
<input type="checkbox"/> hypertension	<input type="checkbox"/> prediabetes																	
<input type="checkbox"/> metabolic syndrome	<input type="checkbox"/> type 2 diabetes																	
<input type="checkbox"/> Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. AND has at least one of the following weight-related comorbidities:	<input type="checkbox"/> other (list): _____																	
<input type="checkbox"/> cardiovascular disease	<input type="checkbox"/> obstructive sleep apnea																	
<input type="checkbox"/> dyslipidemia	<input type="checkbox"/> prediabetes																	
<input type="checkbox"/> hypertension	<input type="checkbox"/> type 2 diabetes																	
	<input type="checkbox"/> other (list): _____																	
<p>2. The beneficiary is less than 18 years of age and: Pre-treatment BMI: _____ Pre-treatment BMI z-score: _____</p> <p><input type="checkbox"/> Has a BMI in the 95th percentile or greater standardized for age and sex based on current CDC charts</p>																		
<p>3. Request is for EVEKEO (amphetamine) or any other Obesity Treatment Agent that contains amphetamine:</p>																		

INITIAL REQUESTS

Was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history
 Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction
 Has a history of trial and failure of or a contraindication or an intolerance to all other Obesity Treatment Agents (preferred and non-preferred)
 Has prescriber documentation explaining why the requested drug is needed and a plan for tapering
 For a beneficiary with a history of substance dependency, abuse, or diversion:
 Has results of a recent UDS for licit and illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances

4. Request is for ANY OTHER NON-PREFERRED Obesity Treatment Agent (i.e., NOT Evekeo [amphetamine] or any other Obesity Treatment Agent that contains amphetamine)
 (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):

Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication
 List medications tried: _____

RENEWAL REQUESTS

1. For a beneficiary 18 years of age or older:
 Pre-treatment weight: _____ Current weight: _____

2. For a beneficiary less than 18 years of age:
 Pre-treatment BMI: _____ Current BMI: _____
 Pre-treatment BMI z-score: _____ Current BMI z-score: _____

3. All requests:

The beneficiary experienced a percent reduction in body weight (for beneficiaries 18 years of age or older) or BMI or BMI z-score (for beneficiaries less than 18 years of age) that is consistent with the recommended cutoff in the FDA-approved package labeling, peer-reviewed medical literature, or consensus treatment guidelines after 3 months of therapy with the maximum recommended/tolerated dose
 The beneficiary experienced an improvement in degree of adiposity or waist circumference from baseline
 The beneficiary experienced clinical benefit with the requested drug in at least one weight-related comorbidity from baseline, such as dyslipidemia, hypertension, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic syndrome, etc.

4. Request is for Evekeo (amphetamine) or any other Obesity Treatment Agent that contains amphetamine:

Has prescriber documentation explaining why the requested drug is needed and a plan for tapering (*submit documentation*)
 For a beneficiary with a history of substance dependency, abuse, or diversion:
 Has results of a recent UDS for licit and illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances

5. Request is for ANY OTHER NON-PREFERRED Obesity Treatment Agent (i.e., NOT Evekeo [amphetamine] or any other Obesity Treatment Agent that contains amphetamine)
 (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):

Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication
 List medications tried: _____

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature: _____	Date: _____
-----------------------------	-------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.